Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab

Table 2 Analytical performances of anti-cetuximab IgE detection by ELISA or FEIA in the severe HSR group of the retrospective cohort. In bold, likelihood ratios over 10 which were considered significant

	ELISA Mariotte D. et al. 2011 [17]	FEIA ImmunoCAP o215
Threshold	> 29 EAU	> 0.1 kU_A/L (defined by the manufacturer)	≥ 0.35 kU_A/L (commonly accepted threshold for sensitization)	≥ 0.525 kU_A/L (defined by the ROC curve)
Se (%)	87.5	87.5	87.5	87.5
Sp (%)	82.1	93.9	95.1	96.3
PPV (%)	33.3	58.3	63.6	70.0
NPV (%)	98.5	98.7	98.7	98.8
pLR	4.89^a	14.4	17.9	23.9
nLR	0.15^a	0.13	0.13	0.13
pPP (%)	19.6^a	44.0	49.6	56.7
nPP (%)	0.80^a	0.70	0.70	0.70

Abbreviations: EAU IgE arbitrary units, nLR Negative likelihood ratio, NPV Negative predictive value, nPP negative post-test probability, pLR Positive likelihood ratio, pPP Positive post-test probability, PPV Positive predictive value, Se Sensitivity, Sp Specificity
^a Parameters not calculated in Mariotte 2011 study

ISSN: 1471-2407